Estimation levels of CTHRC1and some cytokines in Iraqi patients with Rheumatoid Arthritis
Main Article Content
Abstract
Collagen triple helix repeat containing-1 (CTHRC1) is an essential marker for Rheumatoid Arthritis (RA), but its relationship with pro-inflammatory, anti-inflammatory, and inflammatory markers has been scantily covered in extant literature. To evaluate the level of CTHRC1 protein in the sera of 100 RA patients and 25 control and compare levels of tumour necrosis factor alpha (TNF-α), interleukin 10 (IL-10), RA disease activity (DAS28), and inflammatory factors. Higher significant serum levels of CTHRC1 (29.367 ng/ml), TNF-α (63.488 pg/ml), and IL-10 (67.1 pg/ml) were found in patient sera as compared to that in control sera (CTHRC1 = 15.732 ng/ml, TNF-α = 33.788 pg/ml, and IL-10 = 25.122 pg/ml). There was no significant correlation between the level of serum CTHRC1 and DAS28 (r = 0.046, P = 0.650), while there were positive significant correlations between the levels of serum CTHRC1 and CRP (r = 0.372, P = 0.0001), ACPA (r = 0.254, P = 0.01), TNF-α (r = 0.202, P = 0.044), and IL-10 (r = 0.260, P = 0.0001). The level of CTHRC1 (> 25.385 ng/ml) in combination with the levels of CRP and ACPA provided a good indication of RA prediction with sensitivity = 71.0%, specificity = 100.0%, accuracy = 0.71%, positive predictive value (PPV) = 100.0%, and negative predictive value (NPV) = 46.3%. The study showed a significant correlation between the levels of CTHRC1 and TNF-α, and IL-10. These molecules may play a prominent role in the diagnostic and etiology of RA
Received 01/11/2022
Revised 24/12/2022
Accepted 26/12/2022
Published 20/06/2023
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
Petrelli F, Mariani FM, Alunno A, Puxeddu I. Pathogenesis of rheumatoid arthritis: one year in review 2022. Clin Exp Rheumatol; 2022; 40(3). https://doi.org/10.55563/clinexprheumatol/l9lyen.
Jang S, Kwon E-J, Lee JJ. Rheumatoid arthritis: pathogenic roles of diverse immune cells. Int J Mol Sci. 2022; 23(2): 905. https://doi.org/10.3390/ijms23020905.
Al Ghuraibawi ZAG, Sharquie IK, Gorial FI. Diagnostic potential of interleukin-40 (IL-40) in rheumatoid arthritis patients. Egypt. Rheumatol. Elsevier; 2022; 44(4): 377–380. https://doi.org/10.1016/j.ejr.2022.07.007.
Mohammed NUG, Khaleel FM, Gorial FI. The Role of Serum Chitinase-3-Like 1 Protein (YKL-40) Level and its Correlation with Proinflammatory Cytokine in Patients with Rheumatoid Arthritis. Baghdad Sci J. 2022; 19(5): 1014-1020. https://doi.org/10.21123/bsj.2022.6293.
Al-Hashimi NH, Al-Gebori AM, Alosami MHM. Evaluation of the Human Pulmonary Activation-Regulated Chemokine (CCL18/PARC) and Alkaline Phosphatase (ALP) Levels in Iraqi Patients with Rheumatoid Arthritis. Iraqi J Sci. 2020; 713–719. https://doi.org/10.24996/ijs.2020.61.4.1.
Wu C-Y, Yang H-Y, Luo S-F, Lai J-H. From Rheumatoid Factor to Anti-Citrullinated Protein Antibodies and Anti-Carbamylated Protein Antibodies for Diagnosis and Prognosis Prediction in Patients with Rheumatoid Arthritis. Multidisciplinary Digital Publishing Institute. Int J Mol Sci. 2021; 22(2): 686. https://doi.org/10.3390/ijms22020686.
Fabian CBLR. Autoantibodies Associated with Rheumatoid Arthritis: Rheumatoid Factor and Anti-Citrullinated Peptide Antibodies. Juniper Publishers Inc. Open access j orthop rheum. 2019; 14(1): 29–34. https://doi.org/10.19080/OROAJ.2019.14.555880.
Shekhani MT, Forde TS, Adilbayeva A, Ramez M, Myngbay A, Bexeitov Y, et al. Collagen triple helix repeat containing 1 is a new promigratory marker of arthritic pannus. Arthritis Res Ther. Springer. 2016; 18(1): 1–14. https://doi.org/10.1186/s13075-016-1067-1.
Selim ZI, Gamal RM, Araby LA, Badawy ER, Gamal NM. Collagen triple helix repeat containing 1 (CTHRC1) protein: A promising biomarker for evaluation of rheumatoid arthritis patients. Egypt. Rheumatol. Elsevier. 2022; 44(1): 11–14. https://doi.org/10.1016/j.ejr.2021.07.003.
Myngbay A, Bexeitov Y, Adilbayeva A, Assylbekov Z, Yevstratenko BP, Aitzhanova RM, et al. CTHRC1: a new candidate biomarker for improved rheumatoid arthritis diagnosis. Front Immunol Frontiers Media SA. 2019; 10: 1353. https://doi.org/10.3389/fimmu.2019.01353.
Hu T, Liu Y, Tan L, Huang J, Yu J, Wu Y, et al. Value of serum collagen triple helix repeat containing-1 (CTHRC1) and 14-3-3η protein compared to anti-CCP antibodies and anti-MCV antibodies in the diagnosis of rheumatoid arthritis. Br J Biomed Sci. Taylor & Francis. 2021;78(2): 67–71. https://doi.org/10.1080/09674845.2020.1810400.
Stohn JP, Perreault NG, Wang Q, Liaw L, Lindner V. Cthrc1, a novel circulating hormone regulating metabolism. Public Library of Science San Francisco, USA; 2012; 7(10). https://doi.org/10.1371/journal.pone.0047142.
Mizoguchi F, Slowikowski K, Wei K, Marshall JL, Rao DA, Chang SK, et al. Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. Nature Publishing Group. Nat Commun. 2018; 9(1): 1–11. https://doi.org/10.1038/s41467-018-02892-y.
Kimura H, Kwan KM, Zhang Z, Deng JM, Darnay BG, Behringer RR, et al. Cthrc1 is a positive regulator of osteoblastic bone formation. PloS one. Public Library of Science San Francisco, USA. 2008; 3(9). https://doi.org/10.1371/journal.pone.0003174.
Takeshita S, Fumoto T, Matsuoka K, Park K, Aburatani H, Kato S, et al. Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation. J Clin Invest. 2013; 123(9): 3914–3924. https://doi.org/10.1172/JCI69493.
Myngbay A, Manarbek L, Ludbrook S, Kunz J. The role of collagen triple helix repeat-containing 1 protein (CTHRC1) in rheumatoid arthritis. Int J Mol Sci. 2021; 22(5): 2426. https://doi.org/10.3390/ijms22052426.
Masoumi M, Bashiri H, Khorramdelazad H, Barzaman K, Hashemi N, Sereshki HA, et al. Destructive roles of fibroblast-like synoviocytes in chronic inflammation and joint damage in rheumatoid arthritis. Inflammation. Springer. 2021; 44(2): 466–479. https://doi.org/10.1007/s10753-020-01371-1.
Kondo N, Kuroda T, Kobayashi D. Cytokine networks in the pathogenesis of rheumatoid arthritis. Int J Mol Sci. 2021; 22(20): 10922. https://doi.org/10.3390/ijms222010922.
Dissanayake K, Jayasinghe C, Wanigasekara P, Sominanda A. Potential applicability of cytokines as biomarkers of disease activity in rheumatoid arthritis: Enzyme-linked immunosorbent spot assay-based evaluation of TNF-α, IL-1β, IL-10 and IL-17A. PloS one. 2021; 16(1). https://doi.org/10.1371/journal.pone.0246111.
Qu CH, Hou Y, Bi YF, Han QR, Jiao CH, Zou QF. Diagnostic values of serum IL-10 and IL-17 in rheumatoid arthritis and their correlation with serum 14-3-3η protein. Eur Rev Med Pharmacol Sci. 2019; 23(5): 1899–1906.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO, et al. Correction. Ann. Rheum Dis. 2010; 69(10): 1892–1892. https://doi.org/10.1136/ard.2010.138461corr1
van Delft MAM, Huizinga TWJ. An overview of autoantibodies in rheumatoid arthritis. J Autoimmun. 2020; 110: 102392. https://doi.org/10.1016/j.jaut.2019.102392.
Farhan LO, Taha EM, Farhan AM. A Case control study to determine Macrophage migration inhibitor, and N-telopeptides of type I bone collagen Levels in the sera of osteoporosis patients. Baghdad Sci J. 2022; 19(4): 848. https://doi.org/10.21123/bsj.2022.19.4.0848.